Polyoxidonium tablets 12mg, No. 10

Treatment and prevention of acute and chronic respiratory diseases in the stage of exacerbation and remission in adults and children from 3 years old.

As part of complex therapy:

• acute and exacerbations of chronic recurrent infectious and inflammatory diseases of the oropharynx, paranasal sinuses, upper and lower respiratory tract, inner and middle ear;

• allergic diseases complicated by recurrent bacterial, fungal and viral infections (including hay fever, bronchial asthma).

  As monotherapy:

• prevention of recurrent herpes infection of the nasal and labial region;

• prevention of exacerbations of chronic foci of infections of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle ear;

• prevention of secondary immunodeficiencies resulting from aging or exposure to adverse factors.

The drug is administered orally and sublingually 20-30 minutes before meals every day, 2 times / day.

Adults and children over 10 years old are prescribed 1 tab., For children aged 3 to 10 years - 1/2 tab. (With 6 mg).

If necessary, it is possible to carry out repeated courses of therapy in 3-4 months. When the drug is administered again, its effectiveness does not decrease.

Sublingually

For the treatment of influenza and acute respiratory infections, adults and children over 10 years of age are prescribed 1 tab. 2 times / day 7 days; children aged 3 to 10 years - 1/2 tab. 2 times / day 7 days.

For inflammatory diseases of the oral cavity and pharynx, adults are prescribed 1 tab. 2 times / day for 10 days; children over 10 years old - 1 tab. 2 times / day for 7 days; children aged 3 to 10 years - 1/2 tab. 2 times / day for 7 days.

With exacerbation of chronic diseases of the upper respiratory tract, paranasal sinuses, chronic otitis media, adults are prescribed 1 tablet 2 times / day for 10 days; children over 10 years old - 1 tab. 2 times / day for 7 days.

For the treatment of allergic diseases (including hay fever, bronchial asthma), complicated by recurrent bacterial, fungal and viral infections, adults are prescribed 1 tab. 2 times / day for 10 days; children over 10 years old - 1 tab. 2 times / day for 7 days; children aged 3 to 10 years - 1/2 tab. 2 times / day for 7 days.

For the prevention of influenza and acute respiratory infections in the pre-epidemic period, adults are prescribed 1 tablet / day for 10 days; children over 10 years old - 1 tablet / day per day for 7 days; children aged 3 to 10 years - 1/2 tab. / day for 7 days.

For the prevention of recurrent herpes infection of the nasal and labial region, adults are prescribed 1 tab. 2 times / day 10 days; children over 10 years old - 1 tab. 2 times / day 7 days; children aged 3 to 10 years - 1/2 tab. 2 times / day 7 days.

For the prevention of exacerbations of chronic foci of infections of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle ear, adults and children over 10 years old are prescribed 1 tab. 1 time / day 10 days; children aged 3 to 10 years - 1/2 tab. 1 time / day for 10 days.

For the prevention of secondary immunodeficiencies arising from aging or exposure to adverse factors, adults are prescribed 1 tab. 1 time / day for 10 days.

Orally

For diseases of the upper and lower respiratory tract, adults and children over 10 years of age are prescribed 1 tab. 2 times / day for 10 days.

Tablets are white or white with a yellowish tinge, round, flat-cylindrical, with a chamfer, with a line on one side and embossed 'PO' on the other.

1 tab.

azoxymer bromide 12 mg

Excipients: mannitol - 3.6 mg, povidone - 2.4 mg, lactose monohydrate - 185 mg, potato starch - 45 mg, stearic acid - 2 mg.

• Acute renal failure

• children under 3 years old;

• pregnancy;

• lactation period (breastfeeding);

• rare hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome;

• increased individual sensitivity to the drug.

• With caution, the drug should be prescribed for chronic renal failure (used no more than 2 times a week).

pharmachologic effect

Azoximer bromide has a complex effect: immunomodulatory, detoxifying, antioxidant, moderate anti-inflammatory.

The basis of the mechanism of the immunomodulatory action of azoxymer bromide is a direct effect on phagocytic cells and natural killer cells, as well as stimulation of antibody production and synthesis of interferon alpha and interferon gamma.

The detoxifying and antioxidant properties of azoxymer bromide are largely determined by the structure and high-molecular nature of the drug.

Azoximer bromide increases the body's resistance against local and generalized infections of bacterial, fungal and viral etiology. Restores immunity in secondary immunodeficiency conditions caused by various infections, injuries, complications after surgery.

A characteristic feature of azoxymer bromide with local (sublingual) application is the ability to activate the factors of early protection of the body against infection: the drug stimulates the bactericidal properties of neutrophils, macrophages, enhances their ability to absorb bacteria, increases the bactericidal properties of saliva and secretions of the mucous membrane of the upper respiratory tract.

When administered orally, azoximer bromide also activates lymphoid cells in the intestinal lymph nodes.

Azoximer bromide blocks soluble toxic substances and microparticles, has the ability to remove toxins, heavy metal salts from the body, inhibits lipid peroxidation, both by intercepting free radicals and by eliminating catalytically active Fe2 + ions. Azoximer bromide reduces the inflammatory response by normalizing the synthesis of pro- and anti-inflammatory cytokines.

Azoximer bromide is well tolerated, does not possess mitogenic, polyclonal activity, antigenic properties, does not have allergenic, mutagenic, embryotoxic, teratogenic and carcinogenic effects.

Azoximer bromide is odorless and tasteless, does not have a local irritating effect when applied to the mucous membranes of the eye, nose and oropharynx.

Pharmacokinetics

Suction

Azoximer bromide after oral administration is rapidly absorbed from the gastrointestinal tract, the oral bioavailability of the drug is more than 70%. Cmax in blood plasma is reached 3 hours after oral administration. The pharmacokinetics of azoxymer bromide is linear (plasma concentration is proportional to the dose taken).

Distribution

Azoximer bromide is a hydrophilic compound. The apparent Vd is approximately 0.5 L / kg, which indicates that the drug is distributed mainly in the extracellular fluid. The half-absorption period is 35 minutes. Azoximer bromide is rapidly distributed throughout all organs and tissues of the body, penetrates the BBB. There is no cumulative effect.

Metabolism and excretion

In the body of azoxymer, bromide undergoes biodegradation to low molecular weight oligomers, which are excreted mainly by the kidneys, with feces - no more than 3%. T1 / 2 - 18 hours

Side effect

No side effects have been reported.

If the patient has noticed any side effects, he should inform the doctor about it.

Application during pregnancy and lactation

The use of the drug PolyoxidoniumЃ is contraindicated in pregnant women and women during breastfeeding (there is no clinical experience of use).

In experimental studies of the drug PolyoxidoniumЃ in animals, no embryotoxic and teratogenic effects, no effect on fetal development were revealed.

When a pregnancy occurs or is planning a pregnancy, the patient should consult a doctor.

During breastfeeding, the patient should consult a doctor before using PolyoxidoniumЃ.

Application for impaired renal function

The use of the drug is contraindicated in acute renal failure.

With caution, the drug should be prescribed for chronic renal failure (used no more than 2 times a week).

Application in children

The use of the drug in children under 3 years of age is contraindicated.

special instructions

If an allergic reaction develops, the patient should stop using PolyoxidoniumЃ and consult a doctor.

If it is necessary to stop taking the drug Polyoxidonium, cancellation can be carried out immediately, without a gradual dose reduction.

If the next dose of the drug is missed, its subsequent use should be carried out as usual, as indicated in the instructions or recommended by the doctor. Do not take a double dose to compensate for missed doses.

The drug should not be used if there are visual signs of its unsuitability (packaging defect, discoloration of the tablet).

Influence on the ability to drive vehicles and mechanisms

The use of PolyoxidoniumЃ does not affect the ability to perform potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions (including driving, working with moving mechanisms).

Overdose

Overdose cases have not been registered.

Drug interactions

Azoximer bromide does not inhibit cytochrome P450 isoenzymes - CYP1A2, CYP2C9, CYP2C19, CYP2D6, therefore the drug is compatible with antibiotics, antiviral, antifungal and antihistamines, GCS and cytostatics.

If the patient is taking the above or other medications (including over-the-counter), it is necessary to consult a doctor before taking PolyoxidoniumЃ.